Clinical Trial Update: Sitaxsentan in Proteinuric Chronic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of Sitaxsentan in proteinuric chronic kidney disease has completed; the update does not include efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Proteinuria

Drugs mentioned

• Sitaxsentan (sitaxsentan)

Snippet

Sponsor: University of Edinburgh | Conditions: Chronic Kidney Disease, Proteinuria | Phase 2 | Status: COMPLETED